Johnson & Johnson reported strong Q1 2016 earnings, exceeding analyst expectations and raising its EPS guidance for the year. The company showed robust operational sales growth, particularly in its Pharmaceutical and Medical Devices segments, and management expressed confidence in continued margin improvements. These positive results and upbeat outlook are likely to have a positive short-term impact on the stock price.

[1]